NeuroVive completes 10 percent acquisition of Isomerase

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Aug 15, 2016 at 7:45 AM

NeuroVive completes 10 percent acquisition of Isomerase Therapeutics

Lund, Sweden, August 15, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the second step in the previously announced partial acquisition of the British drug discovery and development company Isomerase Therapeutics Ltd (Isomerase), has been completed. NeuroVive now holds approximately 10 percent of the shares in Isomerase. The overall aim with the acquisition is to strengthen the existing partnership and accelerate NeuroVive’s research and development (R&D) program. The now completed acquisition includes approximately 5% further of the shares in Isomerase through a 550 000 GBP cash payment. The first step in the acquisition was executed January 14, 2016 (http://publish.ne.cision.com/Release/ViewReleaseHtml/91E0B436350950EF) when NeuroVive acquired approximately 5 percent of the shares in Isomerase by payment in own shares. NeuroVive is committed to the discovery and development of highly targeted drug candidates that can improve and support mitochondrial function in disease areas with a high medical need. The completed holding in Isomerase is in line with NeuroVive's business strategy of value-adding partnerships with mitochondrial research and development players and commercial partners globally. The joint teams at NeuroVive and Isomerase are currently working on the research project NVP015 (complex I dysfunction) and several other discovery programs which all are progressing well. “We are very happy with how our collaboration with Isomerase has evolved throughout the years. We have together with Isomerase been able to efficiently advance our prioritized research program NVP015 and generate new compounds that currently are evaluated in experimental models”, commented Erik Kinnman, CEO NeuroVive. About Isomerase Isomerase Therapeutics (www.isomerase.co.uk) is an agile drug discovery and development company based in Cambridge, UK and is a leader in the discovery and development of compounds that target molecules such as cyclophilins. The Company is led by an experienced team with a successful track record in the discovery, development and commercialization of drugs by applying a combination of biosynthetic engineering and synthetic chemistry. The team at Isomerase is actively involved in the pharmacology, chemistry and manufacturing for several of NeuroVive’s projects. About NeuroVive NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a company committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of significant therapeutic need. NeuroVive's business approach is driven by value-adding partnerships with mitochondrial research institutions and commercial partners across the globe. NeuroVive's portfolio consists of two clinical projects, one in acute kidney injury (CicloMulsion®) and one in traumatic brain injury (NeuroSTAT®). The candidate drug NeuroSTAT has orphan drug designation in Europe and in the US for treatment of moderate to severe traumatic brain injury and is currently being evaluated in the CHIC study. CicloMulsion is being evaluated in an on-going study, CiPRICS, in acute kidney injury during major surgery. Furthermore, the R&D portfolio consists of two late stage discovery programs and one compound in preclinical development. NeuroVive is listed on Nasdaq Stockholm, Sweden, Small Cap, under the ticker symbol NVP. The share is also traded on the OTC Markets Group Inc market in the US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTCQX Best Market. For investor relations and media questions, please contact: Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard) Fax: +46 (0)46 888 83 48 www.neurovive.com This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 1:30 p.m. CEST on August 15, 2016.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

$4 Million Raised at Miracles for Kids Gala 2026

Anthony Geisler's Impactful Philanthropy Ever heard that old chestnut about putting your money where your mouth is? Well, Anthony Geisler, the chap behind Sequel Brands, sure seems to embody it. At the 2026 Miracles for Kids Night of Miracles Gala, he managed to corral over $4 million for families with critically ill kids. That's no chump change, let me tell you. The...

Frontera Energy's Q3 Results Call: Key Insights Ahead

What to Expect from Frontera’s Upcoming Call Frontera Energy’s got a date with the earnings table, and it’s set for November 11. The story here is about anticipation, folks. This Canadian energy player will lay its third-quarter results bare soon as trading wraps up. They’ll be breaking the nitty-gritty down in a call with the analysts that follows the next day,...

Cork's Market Power Surges in U.S. Wine Industry

Cork: The Unsung Hero of the Wine Bottle You'd think a simple piece of bark couldn't shift the billion-dollar wine industry, but cork closures are doing just that. According to new NielsenIQ data, these natural stoppers are holding their ground as top dogs in the U.S. wine market. Who would've guessed that cork would drive the highest off-premise revenue? That's some...

Sale Shifts Gregg Young Chevrolet to New Owners

Dealership Transition: A New Chapter in Marshalltown Get this—Gregg Young Chevrolet in Marshalltown, Iowa, is changing hands. This isn't some overnight affair; we're talking about a dealership that's been around and has history in the state. The keys are being passed from the Gregg Young Automotive Group to Alan Reuber and Matthew Barrows, under the stewardship of North...

Air Force Officer's Pretrial Solitary Challenged

High Stakes at Joint Base Anacostia-Bolling Let's get real, the courtroom showdown set for November 17 over at Joint Base Anacostia-Bolling isn’t just another blip on the radar. We're talking about Major Jason P. Watson, a seasoned Air Force officer with an unblemished track record and more tours than most folks care to count. Monument Legal is at his side, hammering at...

InsCorp's Steady Q3 Climb Mirrors Strategic Focus

Riding the Revenue Wave Now we're talking about a bank knowing their business—InsCorp, Inc. recently flaunted a 12% year-on-year revenue bump for 3Q26, a testament to a strategy that's clearly sticking. Still, while those numbers are nice and shiny, the detailed breakdown shows earnings per share (EPS) barely budged from last quarter, coming in at $0.73, just a hair...

Why Haunted Attractions Keep Us Coming Back for Fear

Welcome to Fear Incarnated Ah, Kansas City. More than just jazz and barbeque. You’ve got these infamous haunted houses that turn every horror flick into a mere Saturday morning cartoon. Enter Edge of Hell and Beast Haunted Attraction. Two horrifying museums of fear that somehow lure us like flies to sugar from miles away. What's the secret sauce? Well, that’s half the...

Mazu Culture Forum Unveils New Initiatives in China

A Cultural Tapestry Unfurls in Putian Picture this: a kaleidoscope of cultures and ideas unraveling in the coastal city of Putian. The 11th Global Mazu Culture Forum kicks off on October 31, bringing together minds—both fresh and seasoned—from an impressive array of 47 countries and regions. It's more than a forum; it's a vibrant crossroads of innovation, tradition,...

Vuzix to Reveal Q3 2026 Results in Upcoming Call

Vuzix Sets the Stage for Its Q3 2026 Earnings Call Out of all the snazzy tech plays you scribble down on a placemat over morning coffee, Vuzix Corporation (NASDAQ: VUZI) is gearing up for some spotlight action. This November 12, at 4:30 PM Eastern Time, they’re unveiling their third quarter 2026 earnings results, piping hot through a conference call. It's the kind of...

FirstService Unveils New LA Luxury Living Insights

Fresh Insights from Los Angeles' Vertical Living Scene FirstService Residential is throwing the spotlight on luxury high-rises in Los Angeles with their latest episode of Skyline Sessions. Catching wind of this release feels like getting the inside scoop from the horse's mouth—it's about the finer points shaping posh city living in a bustling Californian metropolis....